MannKind

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell MannKind and other ETFs, options, and stocks.

About MNKD

MannKind Corp. is a biopharmaceutical company, which focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. Its products and pipeline include Afrezza, Pediatric Afrezza, V-Go, Tyvaso DPI, MNKD-101, MNKD-201, MNKD-301, and MNKD-501.

CEO

Michael E. Castagna

CEOMichael E. Castagna

Employees

407

Employees407

Headquarters

Danbury, Connecticut

HeadquartersDanbury, Connecticut

Founded

1991

Founded1991

Employees

407

Employees407

MNKD Key Statistics

Market cap

1.71B

Market cap1.71B

Price-Earnings ratio

50.96

Price-Earnings ratio50.96

Dividend yield

—

Dividend yield—

Average volume

7.41M

Average volume7.41M

High today

$5.60

High today$5.60

Low today

$5.31

Low today$5.31

Open price

$5.40

Open price$5.40

Volume

4.16M

Volume4.16M

52 Week high

$7.63

52 Week high$7.63

52 Week low

$3.38

52 Week low$3.38

MNKD News

Simply Wall St 4d

MannKind Pipeline Expansion: Assessing Valuation After New United Therapeutics Collaboration

If you have been watching MannKind (MNKD), the company just shook things up. MannKind announced it is expanding its global license and collaboration agreement w...

TipRanks 6d

MannKind Corporation’s Phase 3 Study: A Potential Game-Changer for Nontuberculous Mycobacterial Infections

MannKind Corporation ((MNKD)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% of...

Analyst ratings

100%

of 8 ratings

Buy

100%

Hold

Sell

People also own

Based on the portfolios of people who own MNKD. This list is generated using Robinhood data, and it’s not a recommendation.